Sept. 4–5, 2019 • Houston, Texas
Building upon the success of 2018’s Interim Workshop on Cancer Immune Responsiveness (CIR), the goal of this year’s CIR workshop was the continued advancement of knowledge in the field about interactions between the immune system and cancer that contribute to immunotherapy response and resistance.
During this two-day workshop, participants took part in both didactic sessions and working groups to identify and address key questions in the field concerning cancer immune responsiveness.
Topics discussed included:
Attendee participation will greatly assist in defining and expanding upon pivotal questions concerning mechanisms of cancer immune responsiveness/resistance in order to advance improved therapeutic strategies and patient benefit with immunotherapy. It is anticipated that the efforts of numerous attendee-driven working groups will further momentum in the field by continuing discussions aimed at addressing the critical questions generated within this workshop well into the future.
This second-year workshop sought to further the suggestions and recommendations derived from the 2018 workshop, educate the scientific community on the status and direction of immunotherapy research related to immune responsiveness and culminate in a manuscript to be submitted for publication in the Journal for ImmunoTherapy of Cancer (JITC).
Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Francesco M. Marincola, MD – Refuge Biotechnologies, Inc.
Upon completion of this meeting, participants will be able to:
The Cancer Immune Responsiveness Task Force hosted a two-day workshop on May 14-15, 2018, that brought together stakeholders to discuss topics including:
Enduring materials from this program are available to the general public. Please click here to access presentations to the program. Presentations and video recordings are available based on permission from presenters.
CIR WORKSHOP SCHEDULE
ACT WORKSHOP SCHEDULE
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com